<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="2576"><DrugName>atosiban</DrugName><DrugNamesKey><Name id="42764250">Antocile</Name><Name id="42938748">Antocin</Name><Name id="42938747">Tractocile</Name><Name id="42938743">atosiban</Name></DrugNamesKey><DrugSynonyms><Name><Value>dTVT</Value></Name><Name><Value>deTVT</Value></Name><Name><Value>CAP-440</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CAP-449</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CAP-476</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Antocile</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>RW-22164</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ORF-22164</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RWJ-22164</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>atosiban</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>Tractocile</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Antocin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>90779-69-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29708">Ferring Pharmaceuticals SA</CompanyOriginator><CompaniesPrimary><Company id="29708">Ferring Pharmaceuticals SA</Company><Company id="1098439">Biopasgroup</Company></CompaniesPrimary><CompaniesSecondary><Company id="17592">RW Johnson Pharmaceutical Research Institute</Company></CompaniesSecondary><CrossReferences><SourceEntity id="2576" type="Drug"><TargetEntity id="140299" type="siDrug">Atosiban acetate</TargetEntity></SourceEntity><SourceEntity id="17592" type="Company"><TargetEntity id="5035523339" type="organizationId">RW Johnson Pharmaceutical Research Institute</TargetEntity></SourceEntity><SourceEntity id="29708" type="Company"><TargetEntity id="4296524617" type="organizationId">Ferring Holding SA</TargetEntity></SourceEntity><SourceEntity id="455" type="ciIndication"><TargetEntity id="O60" type="ICD10"></TargetEntity><TargetEntity id="10036600" type="MEDDRA"></TargetEntity><TargetEntity id="D007752" type="MeSH"></TargetEntity><TargetEntity id="-699701292" type="omicsDisease"></TargetEntity><TargetEntity id="567" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="27" type="Action"><TargetEntity id="329" type="Mechanism">Vasopressin (AVP) Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="298" type="Action"><TargetEntity id="597" type="Mechanism">Oxytocin (OT) Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-01476" type="ciTarget"><TargetEntity id="94838797350213" type="siTarget">Oxytocin receptor</TargetEntity><TargetEntity id="552" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Premature labor - UK - Jun-2000</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="455">Premature labor</Indication></IndicationsPrimary><ActionsPrimary><Action id="298">Oxytocin receptor antagonist</Action><Action id="27">Vasopressin receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="7288">Uterus tone inhibitor</Action></ActionsSecondary><Technologies><Technology id="80">Peptide</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>G2E</Code><Name>LABOUR INHIBITORS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-08T08:20:56.000Z</LastModificationDate><ChangeDateLast>2019-05-13T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="29708" linkType="Company"&gt;Ferring&lt;/ulink&gt; has developed and launched atosiban (Tractocile), an oxytocin antagonist that inhibits uterine contractions induced by oxytocin and vasopressin, for the iv prevention of premature labor. In May 2000, the drug was approved in Spain and by December 2012, it had been launched in Spain [&lt;ulink linkID="1356789" linkType="Reference"&gt;1356789&lt;/ulink&gt;]. In June 2000, the agent was launched in the UK. It had since been launched in Sweden, Germany, Austria, the Netherlands [&lt;ulink linkID="372801" linkType="reference"&gt;372801&lt;/ulink&gt;], [&lt;ulink linkID="356023" linkType="reference"&gt;356023&lt;/ulink&gt;], Denmark, Norway, Finland, Italy, Portugal, Israel and Ireland. In September 2000, the drug was launched in France [&lt;ulink linkID="1345671" linkType="Reference"&gt;1345671&lt;/ulink&gt;]. In October 2001, launches were reported to be imminent in Jordan, Argentina, the Czech Republic, Hungary, Poland and Hong Kong [&lt;ulink linkID="426086" linkType="reference"&gt;426086&lt;/ulink&gt;]. In April 2004, the drug was approved in Latvia [&lt;ulink linkID="1454774" linkType="Reference"&gt;1454774&lt;/ulink&gt;]. In March 2005, the drug was approved in Iceland [&lt;ulink linkID="1452202" linkType="Reference"&gt;1452202&lt;/ulink&gt;] and subsequently launched [&lt;ulink linkID="1450511" linkType="Reference"&gt;1450511&lt;/ulink&gt;]. By November 2017, the drug had been launched in Brazil [&lt;ulink linkID="2121042" linkType="Reference"&gt;2121042&lt;/ulink&gt;]. In October 2007 the drug was approved in Colombia [&lt;ulink linkID="1787507" linkType="Reference"&gt;1787507&lt;/ulink&gt;] and presumed to have been launched by licensee &lt;ulink linkID="1098439" linkType="Company"&gt;Biopas&lt;/ulink&gt; shortly after  [&lt;ulink linkID="1787511" linkType="Reference"&gt;1787511&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="17592" linkType="Company"&gt;RW Johnson&lt;/ulink&gt; was developing atosiban. However, by February 2000, it had discontinued development of the drug [&lt;ulink linkID="357457" linkType="reference"&gt;357457&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In May 2018, &lt;ulink linkID="1053968" linkType="Company"&gt;Hybio Pharmaceutical &lt;/ulink&gt; filed an ANDA for its generic version of atosiban in Europe [&lt;ulink linkID="2149066" linkType="Reference"&gt;2149066&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2013, &lt;ulink linkID="27561" linkType="Company"&gt;Sun Pharmaceutical Industries&lt;/ulink&gt; had submitted a request to the EMA for its generic version of atosiban, Atosiban SUN; in May 2013, the CHMP adopted a positive opinion, recommending the approval of  Sun's generic for the delay of imminent pre-term birth in pregnant adult women [&lt;ulink linkID="1431705" linkType="Reference"&gt;1431705&lt;/ulink&gt;]. In July 2013, the EMA approved Sun's generic atosiban injection (6.75 mg/0.9 ml) [&lt;ulink linkID="1463466" linkType="Reference"&gt;1463466&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;The FDA's Reproductive Health Drugs Advisory Committee met on 20 April 1998, to consider atosiban and decided not to recommend approval. The committee did not feel that the data demonstrated adequate safety for the fetus or premature infant of less than 28 weeks gestation, only 4 panelists were convinced that the drug was safe for the fetus or neonate beyond 28 weeks. The panel asked for further safety and efficacy studies to be conducted [&lt;ulink linkID="282241" linkType="reference"&gt;282241&lt;/ulink&gt;], [&lt;ulink linkID="285765" linkType="reference"&gt;285765&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In May 2000, the drug was approved in Spain and by December 2012, it had been launched in Spain [&lt;ulink linkID="1356789" linkType="Reference"&gt;1356789&lt;/ulink&gt;]. In  June 2000, the drug was launched in Germany [&lt;ulink linkID="372801" linkType="Reference"&gt;372801&lt;/ulink&gt;]; later in September 2000, the drug was launched in France [&lt;ulink linkID="1345671" linkType="Reference"&gt;1345671&lt;/ulink&gt;].   In April 2004, the drug was approved in Latvia [&lt;ulink linkID="1454774" linkType="Reference"&gt;1454774&lt;/ulink&gt;]. In March 2005, the drug was approved in Iceland [&lt;ulink linkID="1452202" linkType="Reference"&gt;1452202&lt;/ulink&gt;] and subsequently launched [&lt;ulink linkID="1450511" linkType="Reference"&gt;1450511&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In October 2011, an sNDA was accepted by the SFDA; it was assumed that launch took placeshortly after its approval there  in April 2012 [&lt;ulink linkID="1342685" linkType="Reference"&gt;1342685&lt;/ulink&gt;], [&lt;ulink linkID="1393918" linkType="Reference"&gt;1393918&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;In November 2012, the drug was approved in Brazil [&lt;ulink linkID="1647989" linkType="Reference"&gt;1647989&lt;/ulink&gt;]. By November 2017, the drug had been launched in Brazil [&lt;ulink linkID="2121042" linkType="Reference"&gt;2121042&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007 the drug was approved in Colombia [&lt;ulink linkID="1787507" linkType="Reference"&gt;1787507&lt;/ulink&gt;] and presumed to have been launched by licensee &lt;ulink linkID="1098439" linkType="Company"&gt;Biopas&lt;/ulink&gt; shortly after [&lt;ulink linkID="1787511" linkType="Reference"&gt;1787511&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;Pharmacological evaluation has been carried out: expression of human recombinant receptors in CHO cells showed that the pKi values at oxytocin receptors, V1a, V1b and V2 receptors were 7.4, 8.5, &amp;lt; 5.3 and 5.9, respectively [&lt;ulink linkID="286912" linkType="reference"&gt;286912&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Dr Juan Piazze, Universita' Degli Studi Di Roma, Roma, Italy&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;3 November 1998&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;The concentration of myometrial and decidual oxytocin receptors increases dramatically in normal women in late pregnancy, causing enhanced uterine sensitivity to physiological levels of oxytocin. Similar increase in myometrial oxytocin receptors has been found in women in preterm labor, indicating a role for oxytocin in idiopathic preterm labor. A new synthesized oxytocin analog, &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt;, has been found to be a competitive inhibitor of oxytocin [&lt;ulink linkType="reference" linkID="14414"&gt;14414&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="77565"&gt;77565&lt;/ulink&gt;]. It is one of the most potent inhibitors of the agonist-induced uterine concentration [&lt;ulink linkType="reference" linkID="172644"&gt;172644&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="172645"&gt;172645&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Ferring's oxytocin antagonist, &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt;, specifically and competitively inhibits guinea pig uterine contractions induced by oxytocin and by vasopressin. Nevertheless, the FDA's Reproductive Health Drugs Advisory Committee met on 20 April 1998, to consider &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; for the short-term management of premature labor and decided, on a vote of 9 to 1, not to recommend approval [&lt;ulink linkType="reference" linkID="282241"&gt;282241&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="285765"&gt;285765&lt;/ulink&gt;]. Further studies are therefore required in order for &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; to obtain this status.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;Fast-atom bombardment-tandem mass spectrometry (FAB-MS-MS) was used to characterize the structure of &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt;, a synthetic oxytocin antagonist, and one of its synthesis-related impurities. The nature of the structural modification in the impurity of interest, replacement of the proline residue by 5-aminovaleric acid, was determined directly from its product ion MS-MS spectrum confirmation of the identity of the impurity was accomplished with GC-MS [&lt;ulink linkType="reference" linkID="14418"&gt;14418&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;2-O-alkyltyrosine-substituted analogs of oxytocin inhibit the in vitro response of the myometrium to axitocin. Using a series of arginine vasopressin and oxytocin analogs it was shown that the substitution of methyl for ethyltyrosine increased the antagonistic properties of the molecule, whereas introduction of a butyl group diminished the effect. &lt;ulink linkType="Drug" linkID="2576"&gt;Atosiban&lt;/ulink&gt; selectively inhibits the effect of oxytocin on human myometrium in vitro [&lt;ulink linkType="reference" linkID="172637"&gt;172637&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="2576"&gt;Atosiban&lt;/ulink&gt; (6 microg/kg/min iv) was administered to chronically instrumented pregnant baboons in the last third of pregnancy; transplacental passage of &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; from mother to fetus was assessed at cesarean section under halothane anesthesia in four baboons and in two chronically instrumented fetuses in the absence of anesthesia. The maternal fetal concentration gradient ranged from 9.2 to 22.8. Maternal &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; clearance rates were 9.2 to 16.9 ml/kg/min [&lt;ulink linkType="reference" linkID="262691"&gt;262691&lt;/ulink&gt;]. The effect of &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; on maternal heart rate was minimal. Maternal blood pressure remained unaltered during &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; infusion. Fetal carotid arterial PO2 was unchanged during 2 h infusion of &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="262691"&gt;262691&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The effect of lateral intracerebroventricular administration of atobisan on the ingestions of glucose was studied in rats that were either non-deprived or deprived of food for 20 h. Significant increases were obtained when &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; (20 nmol/ml) was administration to both deprived (32% increase) and non-deprived (31% increase) rats [&lt;ulink linkType="reference" linkID="267539"&gt;267539&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;Absorption after transdermal administration showed a biphasic pattern in humans, with high initial absorption in the first days [&lt;ulink linkType="reference" linkID="205940"&gt;205940&lt;/ulink&gt;]. A bolus intravenous injection (10 nmol/kg) in humans has a half-life of 16.2 +/- 2.4 min; peak plasma concentrations occurred after 2 to 8 min; total body clearance was to 0.623 +/- 0.099 (SEM) 1/h/kg [&lt;ulink linkType="reference" linkID="172645"&gt;172645&lt;/ulink&gt;]. After intranasal administration (100 nmol/kg/kg) the bioavailability was 10.5 +/- 2.9% with peak plasma concentrations reached after 10 to 45 min [&lt;ulink linkType="reference" linkID="172645"&gt;172645&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Sheep treated with a 2-h infusion of &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; (300 microg/min) reached maximal plasma levels of &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; (585.2 +/- 82.2 ng/ml mean SD) at the end of the infusion period. Levels decreased bi-exponentially with a mean tl/2 alpha of 17 min and mean tl/2 beta of 2.2 h [&lt;ulink linkType="reference" linkID="58013"&gt;58013&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In the rat, the 24 h urinary excretion of &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; was 14.3 to 25.6% of the iv dose and it was negatively correlated with peptide lipophilicity [&lt;ulink linkType="reference" linkID="172644"&gt;172644&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;Transdermal administration of &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; over 6 days showed a biphasic pattern of absorption with high initial absorption during the first 2 days. Atobisan was slightly degraded in the skin reservoir [&lt;ulink linkType="reference" linkID="205940"&gt;205940&lt;/ulink&gt;]. Bolus intravenous injection had a sufficiently long half-life to suggest that this would be a suitable route of administration for the prevention of preterm labor in hospitalized patients [&lt;ulink linkType="reference" linkID="172645"&gt;172645&lt;/ulink&gt;]. Further work needs to establish whether the intranasal route will be of use for outpatients with uterine hyperactivity in late pregnancy and to patients with primary dysmenorrhea. For dysmenorrhegic patients a significant relief of symptoms occurred with intravenous administration of &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; (10 microg/kg) [&lt;ulink linkType="reference" linkID="172645"&gt;172645&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="172647"&gt;172647&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="172652"&gt;172652&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;Two US placebo-controlled trials have been conducted. In PTL096, 246 women who were 20 to 33 weeks pregnant received &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; and 255 received placebo. In women who were at last 28 weeks pregnant &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; was consistently superior to placebo after 48 h. In a second trial of PTL098, randomized patients were treated with &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; or placebo and then maintained on open-label &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt;. Adequate safety was demonstrated [&lt;ulink linkType="reference" linkID="285765"&gt;285765&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side-effects and Contraindications&lt;/subtitle&gt;No significant side-effects were found [&lt;ulink linkType="reference" linkID="58013"&gt;58013&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Encouragingly, &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; does not appear to cross the placenta and should, therefore, be suitable to treat preterm labor. Moreover it has no effect on maternal or fetal cardiovascular parameters. A suitable route of administration needs to be determined in order that &lt;ulink linkType="Drug" linkID="2576"&gt;atosiban&lt;/ulink&gt; can be used in outpatients for the treatment of primary dysmenorrhea. &lt;ulink linkType="Drug" linkID="2576"&gt;Atosiban&lt;/ulink&gt; has also been shown to produce a small, but significant decrease in blood glucose though it is too early to tell whether this effect will be of use in the clinic.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1098439">Biopasgroup</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-10-26T00:00:00.000Z</StatusDate><Source id="1787511" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-18T00:00:00.000Z</StatusDate><Source id="426086" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-18T00:00:00.000Z</StatusDate><Source id="426086" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-18T00:00:00.000Z</StatusDate><Source id="426086" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-06-30T00:00:00.000Z</StatusDate><Source id="372801" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-06-05T00:00:00.000Z</StatusDate><Source id="372801" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-18T00:00:00.000Z</StatusDate><Source id="426086" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-08T00:00:00.000Z</StatusDate><Source id="2121042" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-18T00:00:00.000Z</StatusDate><Source id="426086" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-06-30T00:00:00.000Z</StatusDate><Source id="372801" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><Source id="1438015" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-06-30T00:00:00.000Z</StatusDate><Source id="372801" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="FI">Finland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-18T00:00:00.000Z</StatusDate><Source id="426086" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><Source id="1450511" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-06-30T00:00:00.000Z</StatusDate><Source id="372801" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-09-18T00:00:00.000Z</StatusDate><Source id="1345671" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-18T00:00:00.000Z</StatusDate><Source id="426086" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="455">Premature labor</Indication><Source id="1356789" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-04-21T00:00:00.000Z</StatusDate><Source id="1454774" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17592">RW Johnson Pharmaceutical Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-02-28T00:00:00.000Z</StatusDate><Source id="357457" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17592">RW Johnson Pharmaceutical Research Institute</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-02-28T00:00:00.000Z</StatusDate><Source id="357457" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-05-29T00:00:00.000Z</StatusDate><Source id="1356789" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-18T00:00:00.000Z</StatusDate><Source id="1342685" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-03-01T00:00:00.000Z</StatusDate><Source id="1452202" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1098439">Biopasgroup</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-10-26T00:00:00.000Z</StatusDate><Source id="1787507" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-04-30T00:00:00.000Z</StatusDate><Source id="1342685" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="455">Premature labor</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17592">RW Johnson Pharmaceutical Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-04-08T00:00:00.000Z</StatusDate><Source id="283478" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17592">RW Johnson Pharmaceutical Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="455">Premature labor</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17592">RW Johnson Pharmaceutical Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="455">Premature labor</Indication><Source id="172942" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17592">RW Johnson Pharmaceutical Research Institute</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="455">Premature labor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-02-17T00:00:00.000Z</StatusDate><Source id="356023" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01476"><Name>Oxytocin receptor</Name><SwissprotNumbers><Swissprot>P30559</Swissprot><Swissprot>P32306</Swissprot><Swissprot>P56449</Swissprot><Swissprot>P56494</Swissprot><Swissprot>P70536</Swissprot><Swissprot>P97926</Swissprot><Swissprot>Q28756</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01931"><Name>Vasopressin receptor</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2149066" linkType="reference" linkID="2149066"&gt;2149066&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1077678">ELPEN Pharmaceutical Co Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1098439">Biopasgroup</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29708">Ferring Pharmaceuticals SA</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)Cc2ccc(cc2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O</Smiles></StructureSmiles><Deals><Deal id="130186" title="Ferring and RW Johnson to codevelop atosiban"></Deal><Deal id="149643" title="ELPEN to distribute Ferring's Atosiban, Somatropin and Terlipressin in Greece "></Deal><Deal id="161888" title="Biopas to distribute Ferring Pharmaceuticals' drugs in Colombia                      "></Deal></Deals><PatentFamilies><PatentFamily id="1144931" number="WO-2007086067" title="Method for monitoring tocolytic treatment"></PatentFamily><PatentFamily id="1182924" number="CN-101696236" title="A method for solid phase synthesis of atosiban"></PatentFamily><PatentFamily id="1190358" number="CN-102145162" title="A method for treating a complication of prematurity medicine for injection"></PatentFamily><PatentFamily id="125524" number="WO-2009098707" title="A method of purifying a peptide"></PatentFamily><PatentFamily id="1419051" number="EP-00112809" title="Vasotocin derivatives"></PatentFamily><PatentFamily id="1574901" number="WO-09513802" title="Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor"></PatentFamily><PatentFamily id="1587902" number="WO-2006121362" title="Use of antagonists of oxytocin and/or vasopressin"></PatentFamily><PatentFamily id="1708759" number="CN-102146121" title="Production process of medicine containing an oxytocin antagonist"></PatentFamily><PatentFamily id="2155657" number="IN-201001265" title="Process for preparation of atosiban acetate"></PatentFamily><PatentFamily id="2213482" number="CN-101314613" title="Solid phase synthesis of atosiban"></PatentFamily><PatentFamily id="2652430" number="CN-103421092" title="Atosiban purification method"></PatentFamily><PatentFamily id="2744526" number="WO-2014080032" title="Method and system for diagnosing uterine contraction levels using image analysis"></PatentFamily><PatentFamily id="2785706" number="CN-103980350" title="A method for ring synthesis of atosiban"></PatentFamily><PatentFamily id="2863140" number="CN-104098650" title="Synthesis and application of intermediate atosiban"></PatentFamily><PatentFamily id="3234112" number="CN-105713073" title="Preparation method of atosiban by liquid phase"></PatentFamily><PatentFamily id="3374243" number="CN-105920581" title="Atosiban acetate composition"></PatentFamily><PatentFamily id="3394657" number="CN-105949283" title="Atosiban acetate impurities, preparation and detection method"></PatentFamily><PatentFamily id="3513419" number="CN-106279367" title="A atosiban acetate crystal and preparation method thereof"></PatentFamily><PatentFamily id="3514347" number="CN-106267148" title="A kind of atosiban acetate compound and preparation method thereof"></PatentFamily><PatentFamily id="3691719" number="WO-2017106814" title="Therapeutics for preterm labor management"></PatentFamily><PatentFamily id="369678" number="CN-101357937" title="Preparing method solid phase polypeptide synthesis of atosiban"></PatentFamily><PatentFamily id="4009218" number="CN-104447960" title="A fragment condensation method preparing the atosiban acetate"></PatentFamily><PatentFamily id="4356424" number="CN-109142580" title="Method for measuring related substances of atosiban acetate"></PatentFamily><PatentFamily id="452535" number="WO-2012083861" title="Method for preparing atosiban acetate"></PatentFamily><PatentFamily id="529186" number="WO-2013117122" title="Method for purifying atosiban"></PatentFamily><PatentFamily id="661358" number="CN-101696959" title="Method for measuring content of atosiban acetate, content of preparations thereof and related substances"></PatentFamily><PatentFamily id="697341" number="WO-2005070449" title="Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>9</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>8</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Diagnostic Technologies Ltd" id="1007278"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emcure Pharmaceuticals Ltd" id="1010536"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yangtze River Pharmaceutical Group" id="1024536"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sinopep Pharmaceutical Inc" id="1029947"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Soho-Yiming Pharmaceuticals Co Ltd" id="1037925"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Houston Methodist" id="1041623"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="LanZhou University" id="1047491"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Zhonghe Polypeptide Drugs Research Co. Ltd." id="1053621"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hybio Pharmaceutical Co Ltd" id="1053968"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Medical Sciences &amp; Peking Union Medical College" id="1066199"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenzhen JYMed Technology Co Ltd" id="1066335"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jinan Kanghe Medical Technology Co Ltd" id="1076452"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jier Biochemical (Shanghai) Co Ltd" id="1076957"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Herui Pharmaceutical Co Ltd" id="1077245"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Kangzhou Pharmaceutical Technology Co. Ltd." id="1177597"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Texas System" id="21864"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Texas A&amp;M University System" id="23290"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biocon Ltd" id="28769"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ferring Pharmaceuticals SA" id="29708"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>